Why Should You Attend: Verification and validation requirements have always been part of the US FDA’s GMPs. However, with increasing technology, both industry and regulatory agencies expectations have increased.
Recent high-profile field problems indicate that V&V activities are not planned or carried out as completely as expected, are not documented in a top tier Master Validation Plan, and may not be fully utilizing the power of current risk management tools, as identified in ISO 14971. The FDA / ICH Q-series provide valuable insights for all regulated industries, not just pharma. The billions of dollars spent by industry annually for V&V are not providing the product safety or efficacy seemingly promised. For most companies, the fixes are not rocket-science, but proper up-front V&V planning and execution, documented in a corporate MVP and implemented by other V&V documents.
Areas Covered in the Session:
Verification or Validation - Recent regulatory expectations
The Master Validation Plan and its structure
Product Validation - how it differs from process / equipment V&V
Process / Equipment / Facility Validation - including FDA's recent guidance
When and How to use DQ, IQ, OQ, PQ, or their equivalents
How to use Product Risk Management Tools (per ISO 14971 and ICH Q9)
The 11 key documents for software validation
Incorporating 21 CFR Part 11 requirements
Suggested "test case" formats
Who Will Benefit:
Senior management in Drugs, Devices, Biologics, Dietary Supplements
QA
RA
R&D
Engineering
Production
Operations
Consultants
Recent high-profile field problems indicate that V&V activities are not planned or carried out as completely as expected, are not documented in a top tier Master Validation Plan, and may not be fully utilizing the power of current risk management tools, as identified in ISO 14971. The FDA / ICH Q-series provide valuable insights for all regulated industries, not just pharma. The billions of dollars spent by industry annually for V&V are not providing the product safety or efficacy seemingly promised. For most companies, the fixes are not rocket-science, but proper up-front V&V planning and execution, documented in a corporate MVP and implemented by other V&V documents.
Areas Covered in the Session:
Verification or Validation - Recent regulatory expectations
The Master Validation Plan and its structure
Product Validation - how it differs from process / equipment V&V
Process / Equipment / Facility Validation - including FDA's recent guidance
When and How to use DQ, IQ, OQ, PQ, or their equivalents
How to use Product Risk Management Tools (per ISO 14971 and ICH Q9)
The 11 key documents for software validation
Incorporating 21 CFR Part 11 requirements
Suggested "test case" formats
Who Will Benefit:
Senior management in Drugs, Devices, Biologics, Dietary Supplements
QA
RA
R&D
Engineering
Production
Operations
Consultants
